MedTrace Logo

BALNEOTHERAPY FOR BREAST CANCER PATIENTS UNDERGOING ENDOCRINE THERAPY

NCT06806072 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 96

Last updated 2025-02-03

No results posted yet for this study

Summary

Endocrine therapy is the mainstay of adjuvant therapy in premenopausal women with hormone receptive-positive (HR+) breast cancer as it has been demonstrated that it reduces long-term recurrences and increases survivial. However, this therapy, which suppresses estrogen production and estrogen-induced effects, is associated with the development of joint pain which can significantly reduce quality of life and lead to treatment discontinuation.

The main question the study aims o answer is:

Can balneotherapy (BT) alleviate muscle-skeletal pain (primary objective) derived from endocrine therapy and improve quality of life (secondary objective) in young women with HR+ breast cancer?

Conditions

  • Breast Cancer Early Stage Breast Cancer (Stage 1-3)

Interventions

OTHER

Balneotherapy

The intervention consists in 3 weekly sessions of balneotherapy during 4 weeks.

Sponsors & Collaborators

  • Caldes de Montbui's City Council

    collaborator UNKNOWN

  • European Regional Development Fund

    collaborator OTHER

  • Biomedical Research Networking Center on Frailty and Healthy Aging (CIBERFES)

    collaborator UNKNOWN

  • Parc de Salut Mar

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-10
Primary Completion
2026-08-30
Completion
2027-05-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06806072 on ClinicalTrials.gov